Daiwa Securities Group Forecasts Strong Price Appreciation for Eli Lilly and Company (NYSE:LLY) Stock

Eli Lilly and Company (NYSE:LLY) had its price objective increased by stock analysts at Daiwa Securities Group from $1,230.00 to $1,250.00 in a report released on Wednesday,MarketScreener reports. The brokerage presently has a “buy” rating on the stock. Daiwa Securities Group’s price target indicates a potential upside of 22.82% from the company’s current price.

LLY has been the subject of several other reports. National Bank Financial set a $1,286.00 target price on shares of Eli Lilly and Company in a research report on Monday, December 1st. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 31st. Morgan Stanley upped their price objective on shares of Eli Lilly and Company from $1,290.00 to $1,313.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Finally, Zacks Research cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,219.68.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY traded down $18.31 during midday trading on Wednesday, reaching $1,017.74. 371,301 shares of the company traded hands, compared to its average volume of 3,311,740. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The firm has a market capitalization of $960.10 billion, a price-to-earnings ratio of 44.36, a price-to-earnings-growth ratio of 1.21 and a beta of 0.39. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The firm’s fifty day moving average price is $1,054.36 and its two-hundred day moving average price is $912.40.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the business earned $5.32 earnings per share. Eli Lilly and Company’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Norges Bank acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth $12,976,634,000. Laurel Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after buying an additional 11,537,661 shares during the period. Capital Research Global Investors lifted its holdings in Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after acquiring an additional 4,332,008 shares during the period. J. Stern & Co. LLP grew its position in Eli Lilly and Company by 46,191.3% during the fourth quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock valued at $4,047,245,000 after buying an additional 4,038,502 shares during the period. Finally, Cardano Risk Management B.V. increased its position in shares of Eli Lilly and Company by 876.1% in the fourth quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock valued at $2,552,419,000 after buying an additional 2,131,734 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CSL signed an exclusive licensing agreement with Lilly for clazakizumab, giving Lilly broader rights to develop/commercialize a therapy for complications in end‑stage kidney disease — a near‑term revenue and partnership positive. CSL signs licensing deal with Eli Lilly for clazakizumab to treat kidney disease
• Positive Sentiment: Retevmo showed improved event‑free survival in early‑stage non‑small cell lung cancer and is moving into adjuvant settings — expands label opportunity and adds oncology revenue optionality. Lilly’s rare cancer drug Retevmo looks to broaden reach with adjuvant trial win
• Positive Sentiment: Clinical data reports show Lilly’s experimental lung‑cancer therapy cuts recurrence risk in early‑stage patients — promising efficacy that could support future approvals and uptake. Eli Lilly’s Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients
• Positive Sentiment: Lilly is building supply (reported ~$1.5B inventory) ahead of an expected oral obesity pill approval and planning a global launch, reducing the risk of early shortages that hurt past launches. Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill
• Positive Sentiment: Lilly outlined a $1B investment to build India manufacturing/export capacity, supporting global supply and potentially lowering manufacturing costs long term. Lilly targets India as global export hub amid booming Mounjaro sales, executive says
• Positive Sentiment: Lilly is committing ~ $1B to AI and advanced R&D approaches, which investors view as a long‑term catalyst for faster drug discovery and higher pipeline value. Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery
• Neutral Sentiment: Market commentary notes rising competition in obesity — Lilly’s next‑gen oral orforglipron and retatrutide face intensifying rivals, which could compress future pricing/margin upside if competitive dynamics worsen. Can LLY’s Next-Gen Obesity Pipeline Sustain Growth Amid Competition?
• Neutral Sentiment: Brand/marketing moves such as naming Shaquille O’Neal an ambassador for a Team USA recovery program raise awareness but have limited direct financial impact. Basketball legend Shaquille O’Neal named ambassador for Team USA Athlete Recovery Program in partnership with Eli Lilly
• Neutral Sentiment: Investor events: Lilly confirmed participation in TD Cowen’s health‑care conference (CFO fireside chat), which may provide more management updates but is routine. Lilly to participate in TD Cowen’s 46th Annual Health Care Conference

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.